A Study of Venetoclax (ABT-199) in Combination with | Clinical Research Studies Listing

$A Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia$

Enrolling By Invitation

18 years - 99 years

All

Phase 1

10 participants needed

1 Location

Brief description of study

This study is being done to determine what effects the therapy venetoclax has on acute lymphoblastic leukemia (ALL).This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed ALL.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: B Acute Lymphoblastic LeukemiaLymphoblasts 5 Percent or More of Bone Marrow Nucleated CellsRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaT Acute Lymphoblastic Leukemia
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 830092

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245